SCHEMBL5233155

SCHEMBL5233155

CCOC(=O)c1c(OCC2CCCC2)c2cc(Cl)ccc2c(=O)n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.48
GABRG2 P18507 3/20 0.48
GABRB3 P28472 3/20 0.48
GABRA5 P31644 3/20 0.48
ALDH1A1 P00352 3/20 0.40
ALOX15 P16050 2/20 0.39
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
CASP1 P29466 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PTGER1 P34995 2/20 0.39
MEN1 O00255 1/20 0.39
MAPK10 P53779 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5235297 0.88 GABRA1 (0.47) GABRA1GABRG2GABRB3GABRA5PTGER1
SCHEMBL5239475 0.83 ALDH1A1 (0.44) GABRA1GABRG2GABRB3GABRA5ALDH1A1
SCHEMBL5239006 0.82 GABRA1 (0.44) GABRA1GABRG2GABRB3GABRA5ALDH1A1
SCHEMBL5236655 0.82 ALDH1A1 (0.46) ALDH1A1ALOX15TSHRHSD17B10KDM4E
SCHEMBL5235752 0.80 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5PTGER1
SCHEMBL5240532 0.80 ALDH1A1 (0.43) ALDH1A1ALOX15TSHRHSD17B10KDM4E
SCHEMBL5231871 0.79 GABRA1 (0.42) GABRA1GABRG2GABRB3GABRA5PTGER1
SCHEMBL5240050 0.79 MAOB (0.45) ALDH1A1ALOX15TSHRHSD17B10KDM4E
SCHEMBL5238925 0.79 GABRA1 (0.42) GABRA1GABRG2GABRB3GABRA5MAOB
SCHEMBL7558991 0.78 DPP4 (0.51) GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 GABRA1 3124/4885GABRG2 3321/4885GABRB3 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.